London – Tuesday, April 28, 2026 – The United Kingdom is set to implement substantial policy changes today, with new reforms impacting both social housing and medical research coming into effect. The government has confirmed significant overhauls to the Right to Buy scheme, alongside a major package of reforms for clinical trials.
The Right to Buy initiative, which allows eligible council tenants to purchase their homes at a discount, is undergoing significant changes aimed at better protecting and rebuilding housing stock. Key reforms include increasing the minimum eligibility period for tenants from three to ten years before they can apply to buy their home. Additionally, discount rules are being amended, with discounts starting at 5% and increasing by 1% annually, capped at 15% of the property value or a specified cash limit. A new 35-year exemption period for newly built social homes will also be introduced, preventing them from being sold under Right to Buy for three and a half decades after construction. These measures, announced by the Ministry of Housing, Communities and Local Government, are intended to support councils in their efforts to replenish housing stock while still offering a path to homeownership. The government has also adjusted discount rules and extended the 'cost floor' protection to 30 years, ensuring that sale prices reflect the investment in properties.
In parallel, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) are enacting the most extensive clinical trial reforms in over two decades. Effective from today, these changes aim to expedite patient access to new treatments while maintaining stringent safety standards. The reforms introduce 'notifiable trials,' a fast-track route for lower-risk studies, and legally mandate the Route B substantial modification pathway, which has already demonstrated significantly reduced processing times. These updates are expected to further decrease clinical trial set-up times, which have already seen a reduction from 169 to 122 days. For the first time, the registration of clinical trials and the publication of summary results will become legal requirements, enhancing transparency and accountability within the research sector.
These policy shifts represent a significant moment for the UK, addressing key areas of social housing and healthcare innovation with a forward-looking approach.